Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

November 2014 - FRMC

Department

Conference Insider
11/14/2014

Eileen Koutnik-Fotopoulos

Eileen Koutnik-Fotopoulos
In recent years, medication therapy management (MTM) has become a staple for Medicare Part D. The Patient Protection and Affordable Care Act requires improvements in Part D MTM programs, which are thought to lead to better outcomes in patient...
In recent years, medication therapy management (MTM) has become a staple for Medicare Part D. The Patient Protection and Affordable Care Act requires improvements in Part D MTM programs, which are thought to lead to better outcomes in patient...
In recent years, medication...
11/14/2014
First Report Managed Care
Conference Insider
11/14/2014

Eileen Koutnik-Fotopoulos

Eileen Koutnik-Fotopoulos
Personalized medicine is playing an increasing role in drug development, and many drugs already have biomarkers to treat diseases, particularly cancer, and more are on the horizon.
Personalized medicine is playing an increasing role in drug development, and many drugs already have biomarkers to treat diseases, particularly cancer, and more are on the horizon.
Personalized medicine is playing...
11/14/2014
First Report Managed Care
Conference Insider
11/14/2014

Kerri Fitzgerald

Kerri Fitzgerald
Since the 2013 American College of Cardiology (ACC) and American Heart Association (AHA) joint guidelines were published, debate has ensued.
Since the 2013 American College of Cardiology (ACC) and American Heart Association (AHA) joint guidelines were published, debate has ensued.
Since the 2013 American College...
11/14/2014
First Report Managed Care
Conference Insider
11/14/2014

Kerri Fitzgerald

Kerri Fitzgerald
Boston—Multiple sclerosis (MS) is the most common chronic disease affecting the central nervous system in young adults, and it continues to be a costly burden on the healthcare system in terms of treatment options. During a satellite...
Boston—Multiple sclerosis (MS) is the most common chronic disease affecting the central nervous system in young adults, and it continues to be a costly burden on the healthcare system in terms of treatment options. During a satellite...
Boston—Multiple sclerosis (MS)...
11/14/2014
First Report Managed Care
11/14/2014

Eileen Koutnik-Fotopoulos

Eileen Koutnik-Fotopoulos
Many developed countries with a national health service have a single dominant method used by the national insurer to assess and compare the value of health services. Yet, the United States lacks a uniform system to assess the value of drugs...
Many developed countries with a national health service have a single dominant method used by the national insurer to assess and compare the value of health services. Yet, the United States lacks a uniform system to assess the value of drugs...
Many developed countries with a...
11/14/2014
First Report Managed Care
11/14/2014

Kerri Fitzgerald

Kerri Fitzgerald
Chronic obstructive pulmonary disease (COPD) is the leading cause of morbidity and mortality worldwide, and by 2020, COPD will be the third leading cause of mortality.
Chronic obstructive pulmonary disease (COPD) is the leading cause of morbidity and mortality worldwide, and by 2020, COPD will be the third leading cause of mortality.
Chronic obstructive pulmonary...
11/14/2014
First Report Managed Care
11/14/2014

Kerri Fitzgerald

Kerri Fitzgerald
“[Type 2 diabetes is an] expensive and challenging disease state to treat,” said Ron Dasher, RPh, at the AMCP meeting during a product theater covering the recent approval of empagliflozin.
“[Type 2 diabetes is an] expensive and challenging disease state to treat,” said Ron Dasher, RPh, at the AMCP meeting during a product theater covering the recent approval of empagliflozin.
“[Type 2 diabetes is an]...
11/14/2014
First Report Managed Care
11/14/2014

Kerri Fitzgerald

Kerri Fitzgerald
With an influx of blockbuster drugs coming off patent in the next few years, in 2015, a potential $20.9 billion revenue could be reached for first-time generics.
With an influx of blockbuster drugs coming off patent in the next few years, in 2015, a potential $20.9 billion revenue could be reached for first-time generics.
With an influx of blockbuster...
11/14/2014
First Report Managed Care
11/14/2014

Kerri Fitzgerald

Kerri Fitzgerald
The first FDA-approved biosimilar agent is expected to hit the market in March 2015; however, there are still a number of questions and concerns.
The first FDA-approved biosimilar agent is expected to hit the market in March 2015; however, there are still a number of questions and concerns.
The first FDA-approved...
11/14/2014
First Report Managed Care
11/14/2014

Kerri Fitzgerald

Kerri Fitzgerald
“[Specialty pharmacy] is front page news today,” said Jim Smeeding, RPh, MBA, executive director, NASP, as he opened a session on current trends and future outlooks on the specialty pharmacy industry.
“[Specialty pharmacy] is front page news today,” said Jim Smeeding, RPh, MBA, executive director, NASP, as he opened a session on current trends and future outlooks on the specialty pharmacy industry.
“[Specialty pharmacy] is front...
11/14/2014
First Report Managed Care

Advertisement

Advertisement

Advertisement